GRI Bio Inc (GRI) Actualités

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

GRI Bio to Participate in the Virtual Investor Closing Bell Series

Live webcast on Thursday, December 12th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI...

Form EFFECT - Notice of Effectiveness

GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Workshop, poster and oral presentation of data given as part of the 8th Annual Antifibrotic Drug Development...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form D - Notice of Exempt Offering of Securities

Form 8-K - Current report

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim...

Form 8-K - Current report

GRI Bio Announces Exercise of Warrants

LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...